文献速递乳腺MR

基于BI-RADS v2025手册对术前乳腺MRI评估病变范围的审核可行性研究

Feasibility of Auditing Preoperative Breast MRI for Extent-of-Disease Evaluation Using the BI-RADS v2025 Manual.
PubMed 文献 · Radiology · 2025-01-01

本研究回顾性纳入2021年1月至2022年12月1533例术前乳腺MRI检查,按BI-RADS v2025手册推荐方法计算异常判读率、活检阳性预测值及额外癌症检出率,结果显示审核可行,各指标处于既往有限数据预期范围内。

要点

  • 术前乳腺MRI异常判读率为30.3%(95% CI: 28.0, 32.6),即阳性检查占比。
  • 活检建议阳性预测值(PPV2)为22.8%(95% CI: 19.5, 26.1),基于BI-RADS 4或5类病灶而非检查。
  • 额外癌症检出率为每1000次检查90.7例(95% CI: 74.3, 107.1)。

核心结论

  • 按BI-RADS v2025手册推荐方法审核术前乳腺MRI评估病变范围是可行的,所得指标处于基于有限既往数据的预期范围内。

研究设计与样本

  • 回顾性研究,纳入2021年1月至2022年12月德克萨斯大学MD安德森癌症中心连续术前乳腺MRI检查1533例(中位年龄54.6岁,IQR 45.5-65.2岁,均为女性),排除筛查、诊断、新辅助化疗反应及非诊断或不完整术前MRI。

关键影像表现/征象

  • 464次MRI检查显示609个可疑乳腺病灶,其中432个病灶行后续影像引导活检,检出139个恶性病灶。
  • 年龄较大(OR 1.04;95% CI: 1.02, 1.05;P < .001)与恶性几率升高相关。
  • 存在与索引恶性肿瘤同侧的病灶(OR 1.81;95% CI: 1.20, 2.75;P = .005)与恶性几率升高相关。

诊断标准与关键数值

  • 异常判读率(AIR)为30.3%(95% CI: 28.0, 32.6),即阳性术前MRI检查的百分比。
  • 活检建议阳性预测值(PPV2)为22.8%(95% CI: 19.5, 26.1),即所有不同BI-RADS 4或5类病灶(非检查)中影像引导活检证实为癌的百分比。
  • 活检实施阳性预测值(PPV3)为32.2%(95% CI: 27.8, 36.6),即BI-RADS 4或5类病灶(非检查)中术前影像引导活检显示癌的百分比。
  • 额外癌症检出率(ACDR)为每1000次MRI检查90.7例(95% CI: 74.3, 107.1),即除原发癌外诊断的额外恶性病灶数。

临床应用与阅片要点

  • 七名放射科医生合计花费141小时收集数据并进行审核计算。
  • 审核计算方法按BI-RADS v2025手册描述执行,指标基于病灶而非检查计算PPV2和PPV3。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The forthcoming Breast Imaging Reporting and Data System (BI-RADS) version 2025 (hereafter, v2025) manual recommends auditing breast MRI examinations performed to evaluate the extent of disease in women newly diagnosed with breast cancer. Purpose To investigate the feasibility of this recommended audit using preoperative breast MRI examinations performed over 2 years, report the calculated metrics, and identify any clinical or imaging characteristics associated with improved MRI performance metrics. Materials and Methods Consecutive breast MRI examinations performed from January 2021 to December 2022 at The University of Texas MD Anderson Cancer Center were retrospectively reviewed, excluding screening, diagnostic, neoadjuvant chemotherapy response, and nondiagnostic or incomplete preoperative MRI examinations. Recommended audit calculations were performed as described in the BI-RADS v2025 manual: abnormal interpretation rate (AIR) (percentage of positive preoperative MRI examinations), positive predictive value of biopsies recommended (PPV2) (percentage of all distinct BI-RADS category 4 or 5 findings, not examinations, with a tissue diagnosis of cancer at image-guided biopsy), positive predictive value of biopsies performed (PPV3) (percentage of BI-RADS category 4 or 5 findings, not examinations, with preoperative image-guided biopsy revealing a tissue diagnosis of cancer), and additional cancer detection rate (ACDR) (number of additional malignant lesions diagnosed beyond the primary cancer per 1000 MRI examinations). Total time collecting data and performing calculations was recorded. Characteristics of benign and malignant BI-RADS 4 or 5 lesions were compared using the Wilcoxon rank sum test and Fisher exact test. Logistic regression was used to determine characteristics associated with malignancy. Results A total of 1533 preoperative MRI examinations were included (median patient age, 54.6 years; IQR, 45.5-65.2 years; all female), with 464 MRI examinations revealing 609 suspicious breast findings. Subsequent image-guided biopsy for 432 of these findings revealed 139 malignancies. The overall AIR was 30.3% (95% CI: 28.0, 32.6), overall PPV2 was 22.8% (95% CI: 19.5, 26.1), overall PPV3 was 32.2% (95% CI: 27.8, 36.6), and overall ACDR was 90.7 per 1000 examinations (95% CI: 74.3, 107.1). Seven radiologists spent a combined total of 141 hours collecting data and performing audit calculations. Older patient age (odds ratio, 1.04; 95% CI: 1.02, 1.05; P < .001) and presence of lesions ipsilateral to the index malignancy (odds ratio, 1.81; 95% CI: 1.20, 2.75; P = .005) were associated with higher odds of malignancy. Conclusion Auditing of preoperative breast MRI examinations performed to evaluate disease extent, as recommended in the forthcoming BI-RADS v2025 manual, was feasible and yielded metrics within expected ranges based on limited prior data. © RSNA, 2025.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Cohen EO, Tso HH, Shin K, et al. Feasibility of Auditing Preoperative Breast MRI for Extent-of-Disease Evaluation Using the BI-RADS v2025 Manual. Radiology. 2025. PMID: 41085394. doi:10.1148/radiol.243803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。